MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Behl, C.
Right arrow Articles by Holsboer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Behl, C.
Right arrow Articles by Holsboer, F.

0026-895X/97/040535-07$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 51:535-541 (1997).


ACCELERATED COMMUNICATION
Neuroprotection against Oxidative Stress by Estrogens: Structure-Activity Relationship

Christian Behl, Thomas Skutella, Frank Lezoualc'H, Anke Post, Martina Widmann, Christopher J. Newton, and Florian Holsboer

Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany (C.B., F.L., A.P., M.W., C.J.N., F.H.), and Institute of Anatomy, Charité Berlin, 10098 Berlin, Germany (T.S.)

    Summary
Summary
Introduction
Procedures
Results & Discussion
References

Oxidative stress-induced neuronal cell death has been implicated in different neurological disorders and neurodegenerative diseases; one such ailment is Alzheimer's disease. Using the Alzheimer's disease-associated amyloid beta  protein, glutamate, hydrogen peroxide, and buthionine sulfoximine, we investigated the neuroprotective potential of estrogen against oxidative stress-induced cell death. We show that 17-beta -estradiol, its nonestrogenic stereoisomer, 17-alpha -estradiol, and some estradiol derivatives can prevent intracellular peroxide accumulation and, ultimately, the degeneration of primary neurons, clonal hippocampal cells, and cells in organotypic hippocampal slices. The neuroprotective antioxidant activity of estrogens is dependent on the presence of the hydroxyl group in the C3 position on the A ring of the steroid molecule but is independent of an activation of estrogen receptors.

    Introduction
Summary
Introduction
Procedures
Results & Discussion
References

Ovarian steroids are of prime importance in the normal maintenance of brain function; the loss of these steroids at menopause may account, at least in part, for the cognitive decline and neurodegeneration that are associated with AD (1). Consistent with this are the results of population-based studies, which suggest that the increased incidence of AD in older women may be caused by the deficit of the female sex hormone estrogen after menopause and that the use of estrogen during the postmenopausal period can delay the onset and lower the risk of AD (2). Estrogen acts on a number of different target organs, including the brain, that express specific estrogen receptors, and it is a key modulator of processes involved in differentiation, homeostasis, and development of the female reproductive function (3, 4). In addition to a genomic mode of action via transcriptional activation, estrogen and other steroids, such as progesterone derivatives, have been found to produce short term nongenomic actions. These include the modulation of the electrical properties of neurons and of transmitter release processes (5). The nongenomic antioxidant activity of estrogens has received increasing attention recently (6). Oxidative stress and free radical-mediated cell death have been linked to diseases such as atherosclerosis (7) and to a number of neurodegenerative disorders such as Parkinson's disease and AD (8-11).

Because it has been suggested that estrogens, in contrast to all other natural steroids, are antioxidants of membrane phospholipid peroxidation in cell free systems because of their phenolic structure (6), and because initial data indicate a neuroprotective effect of 17-beta -estradiol in vitro (12, 13), we investigated the neuroprotective potential of estrogen and some of its derivatives against oxidative stress-induced neurodegeneration. Oxidative damage and lipid peroxidation can be caused by the neurotoxic amyloid beta  protein (11) that accumulates in plaques in the brains of AD patients (14) or by excitatory amino acids such as glutamate, which has also been implicated in various neurodegenerative diseases (15), via a glutamate receptor-dependent (16) or a glutamate receptor-independent pathway (17, 18). The latter can be mediated through the induction of an imbalance in antioxidant enzyme systems followed by a reduction in the levels of intracellular antioxidant glutathione in neurons (17, 18). The main goals of this study were 1) to investigate any possible protective effects of estrogen for neurons and 2) to identify a possible structure-activity relationship. Therefore, we tested 17-alpha -estradiol, 17-beta -estradiol, estriol, estrone, ethinyl estradiol, mestranol, quinestrol, and the catechol estrogens 2-OH-estradiol and 4-OH-estradiol (Fig. 1) for their neuroprotective potential against the oxidative stressors Abeta and H2O2. The latter is a mediator of Abeta toxicity (11) and a precursor of highly oxidizing, tissue-damaging radicals such as the lipid peroxidizing hydroxyl radical (19). In addition, glutamate and BSO, which blocks the de novo biosynthesis of glutathione (19), were used.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Molecular structure of estrogens and estrogen derivatives used in the experiments. The 3-OH group on the A ring of the steroid molecule necessary for the neuroprotective activity is highlighted.

    Experimental Procedures
Summary
Introduction
Procedures
Results & Discussion
References

Materials, cell lines, and cell culture. Cells were cultured in DMEM supplemented with 10% fetal calf serum under standard culture conditions. Rat primary cultures from E19 embryonic hippocampi and mouse primary cortical neurons from E19 embryonic cortices were prepared as previously described (11, 21). Primary cells were cultured on poly-L-lysine-coated dishes in a 50% DMEM/50% Ham's F12 medium that contained N2 supplements. Under these minimal culture conditions, more than 90% of the cells were stained positive for neuron-specific enolase. Primary neurons were used after 7-10 days in vitro. Mouse clonal hippocampal HT22 cells were cultivated in DMEM supplemented with 10% fetal calf serum. All media, sera, and medium supplements were from GIBCO (Eggenstein, Germany). The amyloid beta  protein used (fragment 25-35) was from Bachem/Saxon (Hannover, Germany). Glutamate, H2O2, and BSO were from Sigma (Deisenhofen, Germany), as were all other chemicals. Stock solutions for the toxins were prepared and diluted in H2O.

Cytotoxicity and viability assays. Cell viability was assessed using a modified MTT assay as previously described (9, 11, 12). Cell lysis induced by different toxins was assessed with the trypan blue exclusion test followed by cell counting (11, 12). In addition, the fluorescing DNA label PI was used to differentiate between dead cells and living cells (12). All toxicity assays were repeated five times in triplicate determinations. For trypan blue and PI stainings, cells were plated in 60-mm dishes, and the different reagents were added. After 24 hr, trypan blue (at a concentration of 0.12%) or PI (at a concentration of 5 µg/ml) was added, and the number of viable cells (trypan blue-excluding or PI-negative) per low magnification field were determined. For statistical comparisons, analysis of variance followed by a Scheffe's post hoc test was used.

Preparation and culture of organotypic hippocampal slices. Organotypic hippocampal slices were prepared and maintained as previously described (24). Briefly, after decapitation, the brains of 5- to 6-day-old male Sprague-Dawley rats were removed and transferred to cold DMEM. Using a tissue chopper, the hippocampus and the entorhinal cortex were cut into 250-µm slices and were placed on a sterile, porous (0.4 µm) membrane (Millicell; Millipore, Eschborn, Germany). The membranes were transferred into a tissue culture plate and covered with culture medium (final volume 1 ml). The culture medium consisted of 50% DMEM, 25% horse serum, 25% Hanks' balanced salts, and 100 units/ml penicillin/100 µg/ml streptomycin. The culture medium was changed routinely three times a week. Slice cultures were used for experiments after 14 days in vitro.

Detection of intracellular H2O2 and related peroxides. The formation of intracellular peroxides was detected by using DCF-DA as previously described (11, 17). DCF-DA is a nonfluorescent compound that, upon entering cells, is de-esterified and then becomes a substrate to oxidation by intracellular H2O2 and related peroxides. Primary cortical neurons or clonal hippocampal HT22 cells were plated, and toxins were added. After 6 hr, 10 µM DCF-DA was added for 1 hr at 37°. Then, the cells were washed with phenol red-free HEPES-buffered DMEM supplemented with 2% fetal calf serum, and the cultures were viewed with a fluorescence microscope using fluorescein optics. Cultures were compared with treatment condition by an observer blinded to the study, and fluorescence was determined qualitatively by counting the cells first under PC and then under fluorescence. For quantification, >200 cells per low magnification field were counted in five separate experiments, fluorescing cells were determined, and results were expressed as the percentage of fluorescent cells.

    Results and Discussion
Summary
Introduction
Procedures
Results & Discussion
References

Rat primary hippocampal neurons and mouse clonal hippocampal HT22 cells pretreated for 20 hr with 10 µM 17-beta -estradiol, estriol, or estrone and with the nonestrogenic stereoisomer 17-alpha -estradiol, which does not bind to estrogen receptors and is therefore biologically inactive (20), were protected against a 24-hr challenge by Abeta 25-35 (2 µM), the toxic fragment of Abeta (21) (Fig. 2, A and B). Cells of both of these hippocampal cell culture systems were also protected against H2O2 (30 µM or 60 µM) and BSO (500 µM) by these estrogens (Table 1 and data not shown). A significant increase in cell survival (p < 0.01) could only be observed at the 10-µM concentration of these estrogens. Lower concentrations were not effective, as shown in detail for the survival of HT22 cells that were pretreated with ethinyl estradiol after a challenge with either BSO, Abeta 25-35, or glutamate (Fig. 2C)


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Different estrogens protect rat primary hippocampal neurons (A) and mouse clonal hippocampal cells (HT22) (B) against Abeta -induced cell death. Primary neurons and HT22 cells were plated and pretreated with the indicated estrogens (10 µM) for 20 hr. Then, cultures were challenged with 2 µM Abeta 25-35 for an additional 20 hr, and neuronal survival was determined by performing MTT assays as previously described (9, 11, 12). C, HT22 cells were preincubated for 20 hr with increasing concentrations of ethinyl estradiol and then challenged by either 500 µM BSO ([triaf]), 2 µM Abeta 25-35 (bullet ), or 1 mM glutamate (black-square) for 20 hr, and MTT assays were performed. Results are expressed as the percentage of reduction of MTT relative to the corresponding control. The experimental data are presented as triplicate determinations across five independent experiments (mean ± standard error). Comparisons between cultures incubated with estrogens (or ethanol) alone and cultures treated with estrogens (or ethanol) plus toxin were made by analysis of variance followed by a Scheffe's post hoc test. *, p < 0.01 (considered significant). A final concentration of 0.1% of the steroid solvent ethanol was not toxic to the cells and did not interfere either with the toxins or with the MTT reduction. An increase in cell survival caused by treatment with the estrogens alone was below 10% in these short time assays.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Protection of hippocampal neurons against oxidative stress-induced cell death by different estrogens

HT22 cells and primary cortical neurons were incubated with the various estrogens, and testosterone for 20 hr at 10 µM before the indicated toxins were added. After 6 hr, the intracellular formation of H2O2 and related peroxides was determined using DCF fluorescence. Parallel cultures were treated for an additional 14 hours. At that time, either the reduction of MTT as a measure of cellular viability (9, 11, 12) or trypan blue exclusion and cell countings as a measure of cell lysis (11, 12) was performed. The data in parentheses refer to the treatment of the cells with H2O2. Steroids did not interfere with the colorimetric MTT assay. All results were normalized to control values (no addition of reagent) as 100. The data of the survival assays are presented as means ± standard error of five independent experiments. Peroxide formation as detected with DCF fluorescence is expressed as percent fluorescent cells. Presented data are the means ± standard error of five independent experiments. Comparisons were made by ANOVA followed by a Scheffe's post hoc test.

17-alpha -Estradiol, ethinyl estradiol, quinestrol, mestranol, and the catechol estrogens 2-OH-estradiol and 4-OH-estradiol were tested for their neuroprotective activity at 1 µM and 10 µM against BSO and H2O2 in mouse primary cortical neurons and against glutamate and H2O2 in HT22 cells. Estradiol is rapidly converted to 2-OH- and 4-OH-estradiol by an NADPH-dependent cytochrome P450-linked monooxygenase system in vivo (22). All tested estrogens that carry an OH group at the C3 position on the A ring of the steroid molecule afforded neuroprotection in these experimental paradigms at a concentration of 10 µM (Fig. 3; Table 1). Again, steroid concentrations lower than 10 µM did not afford protection, as shown in detail for ethinyl estradiol (Fig. 2C). Steroid molecules with an ether-modified OH group at the C3 position (Fig. 1), such as the 17-alpha -ethinyl estradiols quinestrol (3-cyclopentyl ether) or mestranol (3-methyl ether) and testosterone with a keto group at the C3 position, did not prevent oxidative stress-induced cell death (Fig. 3; Table 1). After the glutamate challenge, PC microscopy revealed dramatic changes in cellular morphology, and PI stainings demonstrated cell death of the clonal hippocampal HT22 cells. Some experimental data argue for a receptor-independent pathway of neuroprotection by estrogens because 1) the addition of the estrogens 2 or 20 hr before the toxic challenge did not influence the protection afforded (data not shown), 2) high concentrations must be used to achieve a protective effect, 3) the addition of actinomycin D as the inhibitor of RNA synthesis did not block the protective effect (data not shown), 4) HT22 cells that lack endogenous estrogen receptors can be protected (12), and 5) 17-alpha -estradiol, which does not bind to estrogen receptors, is also neuroprotective.


View larger version (74K):
[in this window]
[in a new window]
 
Fig. 3.   17-alpha -Estradiol (17-alpha E), 17-beta -estradiol (17-beta E), and ethinyl estradiol (EE) prevent glutamate-induced intracellular accumulation of H2O2 and related peroxides and, ultimately, cell death in clonal hippocampal HT22 cells, whereas the ethinyl estradiol mestranol (M) is not protective. HT22 cells were plated in 60-mm dishes and either pretreated with the indicated estrogens (10 µM) for 20 hr or left untreated. Cells were challenged with 1 mM glutamate, and intracellular peroxide formation was determined after 6 hr using DCF stainings, as described in Experimental Procedures. After an additional 14 hr, parallel cultures were stained for dead cells, using PI at 5 µg/ml, as previously reported (12). Magnification of PC, PI, and DCF images is 100×.

Incubation of primary cortical neurons with Abeta and BSO, and treatment of HT22 cells with glutamate induced an intracellular accumulation of H2O2 and related peroxides (11) that can be detected with DCF stainings after 6 hr. This increase could be blocked by the preincubation of cells with different estrogens, as shown qualitatively in Fig. 3 and quantitatively in Table 1. Peroxides are precursors of the highly reactive, lipid-peroxidizing hydroxyl radical (19). Estrogens with an intact 3-OH group on the A ring significantly reduced the percentage of fluorescent cells after the glutamate challenge (p < 0.05), whereas quinestrol, mestranol, and testosterone were inactive and could not block these intracellular oxidative events, which is consistent with a lack of protective activity (Fig. 3; Table 1).

The hippocampus is a major target of neuronal cell death in neurodegenerative disorders such as AD (23). Organotypic hippocampal slice cultures from postnatal rats preserve the intrinsic connections and regional differentiation specific to the hippocampus in vivo and are frequently used for the investigation of neurotoxins (24). These cultures were established and pretreated with the different estrogens for 20 hr, followed by a strong oxidative challenge with 250 µM H2O2 for 24 hr that induced massive neuronal death in the gyrus dentatus region and the cornu ammonis region (Fig. 4A). The different 3-OH-containing estrogens protected the neuronal cells in the hippocampal slice, as exemplified by ethinyl estradiol, whereas its ether-modified derivatives quinestrol, mestranol, and testosterone were not protective (Fig. 4; data not shown).


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 4.   Ethinyl estradiol prevents H2O2-induced oxidative cell death in organotypic hippocampal slice cultures. Organotypic hippocampal slices were pretreated for 24 hr with either 10 µM mestranol (B), quinestrol (C) (both of which had ether-modified 3-OH groups on the A ring), or ethinyl estradiol (D) (intact 3-OH group on the A ring). A, A slice challenged with H2O2 without further pretreatment. Then, 250 µM H2O2 was added to the slices; after 24 hr, cell death was determined by using PI (5 µg/ml). Images were obtained by using a fluorescence microscope (40×) and UV filters. Red, PI-positive (dead) cells. Arrows, gyrus dentatus region; CA, cornuammonis region.  

In neuronal systems, estrogens can exert long term trophic actions and can stimulate the secretase metabolism of the amyloid beta  precursor protein via transcriptional activation after the binding of the estrogen receptor to estrogen-responsive elements on the DNA (25-27). These genomic actions of estrogen could potentially affect the AD risk. We report that estrogen and estrogen derivatives within the hydroxyl group in the C3 position on the A ring of the steroid molecule can also act as powerful neuroprotectants in an estrogen-receptor-independent short term manner because of to their antioxidative capacity. The concentrations required for a significant antioxidative neuroprotection in our in vitro system are higher than the estrogen levels that occur naturally in vivo but are consistent with those that have been previously shown to have antioxidant activity in different cellular and cell-free systems (6, 12). Plasma concentrations of 17-beta -estradiol are in the nanomolar range, depending on sex and menopausal status (28). Interestingly, 17-beta -estradiol has been shown to be a more potent antioxidant inhibitor (IC50 = 21 µM) of iron-catalyzed lipid peroxidation in rat brain homogenates than vitamin E (IC50 = 30 µM) (29); the latter is currently being tested in a clinical AD trial. Nevertheless, as shown for the steroid compound RU486 after oral administration, micromolar steroid concentrations can be attained in vivo (30).

It is of great significance that the neuroprotective effect against oxidative stressors in the different neuronal in vitro systems is also afforded by the nonestrogenic 17-alpha -estradiol, a compound that is biologically inactive with respect to binding to the estrogen receptor (20). In summary, our results pin down the neuroprotective activity of estrogens to the presence of the 3-OH group of the A ring in the steroid molecule and may therefore serve as a basis for the design and synthesis of other nonestrogenic antioxidants. One example could be the synthesis of estrogens with bulky alkyl substituents in both the 2- and 4-position on the A ring that do not bind to the estrogen receptor but that nevertheless exert an antioxidant potential (31).

    Acknowledgments

We thank R. Rupprecht for helpful comments on the manuscript. We are grateful to P. Maher (Scripps Research Institute, LaJolla, CA) for supplying the HT22 cells.

    Footnotes

Received November 6, 1996; Accepted January 2, 1997

   F.L. was supported by a postdoctoral fellowship from Institute National de la Santé et de la Recherche Médicale. This work was supported in part by a grant of the Wilhelm-Woort-Stiftung für Alternsforschung (C.B.).

Send reprint requests to: Christian Behl, Max Planck Institute of Psychiatry, Clinical Institute, 80804 Munich, Germany. E-mail: chris{at}mpipsykl.mpg.de

    Abbreviations

AD, Alzheimer's disease; BSO, buthionine sulfoximine; DMEM, Dulbecco's modified Eagle's medium; PI, propidium iodide; PC, phase contrast; DCF, dichlorofluorescein; DCF-DA, 2',7'-dichlorofluorescein diacetate; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.

    References
Summary
Introduction
Procedures
Results & Discussion
References

1. Simpkins, J. W., M. Singh, and J. Bishop. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol. Aging Suppl.  15:195-197 (1994).
2. Paganini-Hill, A. and V. W. Henderson. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol.  140:256-261 (1994)[Abstract/Free Full Text].
3. McEwen, B. S. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci.  12:141-147 (1991)[Medline].
4. Clark, J. H. and E. J. Peck. Female sex steroids, receptors and function. Monogr. Endocrinol.  14:4-36 (1979).
5. Paul, S. M. and R. H. Purdy. Neuroactive steroids. FASEB J.  6:2311-2322 (1992)[Abstract].
6. Ravi Subbiah, M. T., B. Kessel, M. Agrawal, R. Rajan, W. Abplanalp, and Z. Rymaszewski. J. Clin. Endocrinol. Metab.  77:1095-1097 (1993)[Abstract].
7. Parthasarathy, S., D. Steinberg, and J. L. Witztum. The role of oxidated low-density lipoproteins in the pathogenesis of atherosclerosis. Annu. Rev. Med.  43:219-225 (1992)[Medline].
8. Coyle, J. T. and P. Puttfarcken. Oxidative stress, glutamate, and neurodegenerative disorders. Science (Washington D. C.)  262:689-695 (1993)[Abstract/Free Full Text].
9. Yan, S. D., X. Cheng, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, A. Migheli, P. Nawroth, D. Stern, and A. M. Schmidt. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (Lond.)  382:685-691 (1996)[Medline].
10. Miyata, M. and J. D. Smith. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta -amyloid peptides. Nat. Gen.  14:55-61 (1996)[Medline].
11. Behl, C., J. B. Davis, R. Lesley, and D. Schubert. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell  77:817-827 (1994)[Medline].
12. Behl, C., M. Widmann, T. Trapp, and F. Holsboer. 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun.  216:473-482 (1995)[Medline].
13. Goodman, Y., A. J. Bruce, B. Cheng, and M. Mattson. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta -peptide toxicity in hippocampal neurons. J. Neurochem.  66:1836-1844 (1996)[Medline].
14. Glenner, G. G. Alzheimer's disease: its proteins and genes. Cell  52:307-308 (1988)[Medline].
15. Choi, D. W. Excitotoxic cell death. J. Neurobiol.  23:1261-1276 (1992)[Medline].
16. Lafon-Cazal, M., S. Pietri, M. Culcasi, and J. Bockaert. NMDA-dependent superoxide production and neurotoxicity. Nature (Lond.)  364:535-537 (1993)[Medline].
17. Murphy, T. H., M. Miyamoto, A. Sastre, R. L. Schnaar, and J. T. Coyle. Glutamate toxicity in a neural cell line involves inhibition of cystine transport leading to oxidative stress. Neuron  2:1547-1558 (1989)[Medline].
18. Davis, J. B. and P. Maher. Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res.  652:169-173 (1994)[Medline].
19. Halliwell, B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radical Biol. Med.  7:645-651 (1989)[Medline].
20. Gorski, J. A hindsight view of early studies on the estrogen receptor: a personal history. Steroids  59:240-243 (1994)[Medline].
21. Yankner, B. A., L. K. Duff, and D. A. Kirschner. Neurotrophic and neurotoxic effects of myeloid beta protein: reversal by tachykinin neuropeptides. Science (Washington D. C.)  250:279-282 (1990)[Abstract/Free Full Text].
22. Jellinck, P. H., J. J. Michnovicz, and H. L. Bradlow. Influence of indole-3-carbinol on the hepatic microsomal formation of catechol estrogens. Steroids  56:446-450 (1991)[Medline].
23. Braak, H. and E. Braak. Neuropathological staging of Alzheimer-related changes. Acta. Neuropathol.  82:239-259 (1991)[Medline].
24. Diekmann, S., R. Nitsch, and T. G. Ohm. The organotypic entorhinal-hippocampal complex slice culture of adolescent rats. A model to study transcellular changes in a circuit particularly vulnerable in neurodegenerative disorders. J. Neural Transm. Suppl.  44:61-71 (1994)[Medline].
25. Ferreira, A. and A. Caceres. Estrogen-enhanced neurite growth: evidence for a selective induction of tau and stable microtubules. J. Neurosci.  11:392-402 (1991)[Abstract].
26. Jaffe, A. B., C. D. Toran-Allerand, P. Greengard, and S. E. Gandy. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem.  269:13065-13068 (1994)[Abstract/Free Full Text].
27. Honjo, H., K. Tanaka, T. Kashiwagi, M. Urabe, H. Okada, M. Hayashi, and K. Hayashi. Senile dementia---Alzheimer's type and estrogen. Hormone Metab. Res.  27:204-207 (1995)[Medline].
28. Milgrom, E. Steroid hormones, in Hormones---From Molecules to Disease (E.-E. Baulieu and P. A. Kelly, eds.). Chapman and Hall, New York, 387-437 (1990).
29. Hall, E. D., K. E. Pazara, and K. L. Linseman. Sex differences in postischemic neuronal necrosis in gerbils. J. Cereb. Blood Flow Metab.  11:292-298 (1991)[Medline].
30. Heikinheimo, O. and R. Kekkonen. Dose-response relationships of RU-486. Ann. Med.  25:71-76 (1993)[Medline].
31. Miller, C. P., I. Jirkovsky, D. A. Hayhurst, and S. J. Adelman. In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein. Steroids  61:305-308 (1996)[Medline].


Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
MutagenesisHome page
J. A. Lemon, C. D. Rollo, N. M. McFarlane, and D. R. Boreham
Radiation-induced apoptosis in mouse lymphocytes is modified by a complex dietary supplement: the effect of genotype and gender
Mutagenesis, November 1, 2008; 23(6): 465 - 472.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. M. Flynn, S. D. Dimitrijevich, M. Younes, G. Skliris, L. C. Murphy, and P. R. Cammarata
Role of wild-type estrogen receptor-{beta} in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells
Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E637 - E647.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Razmara, L. Sunday, C. Stirone, X. B. Wang, D. N. Krause, S. P. Duckles, and V. Procaccio
Mitochondrial Effects of Estrogen Are Mediated by Estrogen Receptor {alpha} in Brain Endothelial Cells
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 782 - 790.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al.
Estrogen Receptors: How Do They Signal and What Are Their Targets
Physiol Rev, July 1, 2007; 87(3): 905 - 931.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Satoh, C. M. Matter, H. Ogita, K. Takeshita, C.-Y. Wang, G. W. Dorn II, and J. K. Liao
Inhibition of Apoptosis-Regulated Signaling Kinase-1 and Prevention of Congestive Heart Failure by Estrogen
Circulation, June 26, 2007; 115(25): 3197 - 3204.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Numakawa, T. Matsumoto, D. Yokomaku, T. Taguchi, E. Niki, H. Hatanaka, H. Kunugi, and T. Numakawa
17{beta}-Estradiol Protects Cortical Neurons Against Oxidative Stress-Induced Cell Death through Reduction in the Activity of Mitogen-Activated Protein Kinase and in the Accumulation of Intracellular Calcium
Endocrinology, February 1, 2007; 148(2): 627 - 637.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise
Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies
Endocr. Rev., October 1, 2006; 27(6): 575 - 605.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X. Wang, J. A. Dykens, E. Perez, R. Liu, S. Yang, D. F. Covey, and J. W. Simpkins
Neuroprotective Effects of 17beta-Estradiol and Nonfeminizing Estrogens against H2O2 Toxicity in Human Neuroblastoma SK-N-SH Cells
Mol. Pharmacol., July 1, 2006; 70(1): 395 - 404.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
L. B. J. Morales, K. K. Loo, H.-b. Liu, C. Peterson, S. Tiwari-Woodruff, and R. R. Voskuhl
Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis.
J. Neurosci., June 21, 2006; 26(25): 6823 - 6833.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. B. Dubal, S. W. Rau, P. J. Shughrue, H. Zhu, J. Yu, A. B. Cashion, S. Suzuki, L. M. Gerhold, M. B. Bottner, S. B. Dubal, et al.
Differential Modulation of Estrogen Receptors (ERs) in Ischemic Brain Injury: A Role for ER{alpha} in Estradiol-Mediated Protection against Delayed Cell Death
Endocrinology, June 1, 2006; 147(6): 3076 - 3084.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
Y. Merot, F. Ferriere, E. Debroas, G. Flouriot, D. Duval, and C. Saligaut
Estrogen receptor alpha mediates neuronal differentiation and neuroprotection in PC12 cells: critical role of the A/B domain of the receptor
J. Mol. Endocrinol., October 1, 2005; 35(2): 257 - 267.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K. M. Dhandapani, F. M. Wade, V. B. Mahesh, and D. W. Brann
Astrocyte-Derived Transforming Growth Factor-{beta} Mediates the Neuroprotective Effects of 17{beta}-Estradiol: Involvement of Nonclassical Genomic Signaling Pathways
Endocrinology, June 1, 2005; 146(6): 2749 - 2759.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. G. Smith, L. Betancourt, and Y. Sun
Molecular Endocrinology and Physiology of the Aging Central Nervous System
Endocr. Rev., April 1, 2005; 26(2): 203 - 250.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot
Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells
Endocrinology, February 1, 2005; 146(2): 889 - 900.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. E. Jung, M. B. Gatch, and J. W. Simpkins
Estrogen Neuroprotection Against the Neurotoxic Effects of Ethanol Withdrawal: Potential Mechanisms
Experimental Biology and Medicine, January 1, 2005; 230(1): 8 - 22.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. A. Sortino, M. Chisari, S. Merlo, C. Vancheri, M. Caruso, F. Nicoletti, P. L. Canonico, and A. Copani
Glia Mediates the Neuroprotective Action of Estradiol on {beta}-Amyloid-Induced Neuronal Death
Endocrinology, November 1, 2004; 145(11): 5080 - 5086.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Kurata, M. Takebayashi, S. Morinobu, and S. Yamawaki
{beta}-Estradiol, Dehydroepiandrosterone, and Dehydroepiandrosterone Sulfate Protect against N-Methyl-D-aspartate-Induced Neurotoxicity in Rat Hippocampal Neurons by Different Mechanisms
J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 237 - 245.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. Zitzler, D. Link, R. Schafer, W. Liebetrau, M. Kazinski, A. Bonin-Debs, C. Behl, P. Buckel, and U. Brinkmann
High-throughput Functional Genomics Identifies Genes That Ameliorate Toxicity Due to Oxidative Stress in Neuronal HT-22 Cells: GFPT2 Protects Cells Against Peroxide
Mol. Cell. Proteomics, August 1, 2004; 3(8): 834 - 840.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
R. I. Fernando and J. Wimalasena
Estradiol Abrogates Apoptosis in Breast Cancer Cells through Inactivation of BAD: Ras-dependent Nongenomic Pathways Requiring Signaling through ERK and Akt
Mol. Biol. Cell, July 1, 2004; 15(7): 3266 - 3284.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Y. Zhang, N. Champagne, L. K. Beitel, C. G. Goodyer, M. Trifiro, and A. LeBlanc
Estrogen and Androgen Protection of Human Neurons against Intracellular Amyloid {beta}1-42 Toxicity through Heat Shock Protein 70
J. Neurosci., June 9, 2004; 24(23): 5315 - 5321.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. W. Rau, D. B. Dubal, M. Bottner, L. M. Gerhold, and P. M. Wise
Estradiol Attenuates Programmed Cell Death after Stroke-Like Injury
J. Neurosci., December 10, 2003; 23(36): 11420 - 11426.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. S. Soldan, A. I. A. Retuerto, N. L. Sicotte, and R. R. Voskuhl
Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol
J. Immunol., December 1, 2003; 171(11): 6267 - 6274.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. W. Rau, D. B. Dubal, M. Bottner, and P. M. Wise
Estradiol Differentially Regulates c-Fos after Focal Cerebral Ischemia
J. Neurosci., November 19, 2003; 23(33): 10487 - 10494.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Prokai, K. Prokai-Tatrai, P. Perjesi, A. D. Zharikova, E. J. Perez, R. Liu, and J. W. Simpkins
Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection
PNAS, September 30, 2003; 100(20): 11741 - 11746.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
B. R. Bhavnani, M. Berco, and J. Binkley
Equine Estrogens Differentially Prevent Neuronal Cell Death Induced by Glutamate
Reproductive Sciences, July 1, 2003; 10(5): 302 - 308.
[Abstract] [PDF]


Home page
Exp. Biol. Med.Home page
L. Zhao, S. Chen, and R. D. Brinton
An Estrogen Replacement Therapy Containing Nine Synthetic Plant-Based Conjugated Estrogens Promotes Neuronal Survival
Experimental Biology and Medicine, July 1, 2003; 228(7): 823 - 835.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. A. Shumaker, C. Legault, S. R. Rapp, L. Thal, R. B. Wallace, J. K. Ockene, S. L. Hendrix, B. N. Jones III, A. R. Assaf, R. D. Jackson, et al.
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial
JAMA, May 28, 2003; 289(20): 2651 - 2662.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. R. Rapp, M. A. Espeland, S. A. Shumaker, V. W. Henderson, R. L. Brunner, J. E. Manson, M. L. S. Gass, M. L. Stefanick, D. S. Lane, J. Hays, et al.
Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial
JAMA, May 28, 2003; 289(20): 2663 - 2672.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
X. Wang, J. W. Simpkins, J. A. Dykens, and P. R. Cammarata
Oxidative Damage to Human Lens Epithelial Cells in Culture: Estrogen Protection of Mitochondrial Potential, ATP, and Cell Viability
Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2067 - 2075.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. W. Cousins, M. E. Marin-Castano, D. G. Espinosa-Heidmann, A. Alexandridou, L. Striker, and S. Elliot
Female Gender, Estrogen Loss, and Sub-RPE Deposit Formation in Aged Mice
Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1221 - 1229.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
R. Thuillier, Y. Wang, and M. Culty
Prenatal Exposure to Estrogenic Compounds Alters the Expression Pattern of Platelet-Derived Growth Factor Receptors {alpha} and {beta} in Neonatal Rat Testis: Identification of Gonocytes as Targets of Estrogen Exposure
Biol Reprod, March 1, 2003; 68(3): 867 - 880.
[Abstract] [Full Text] [PDF]